Reports Q4 & FY2025 Results with Significant Skin Health Impairment; Issues 2026 Guidance

summarizeSummary

Colgate-Palmolive reported a Q4 GAAP EPS loss and a full-year decline due to a $794 million skin health impairment charge, though underlying sales and non-GAAP EPS showed growth, and 2026 guidance is positive.

check_boxKey Events

• Q4 GAAP EPS Loss

  Reported a fourth-quarter GAAP EPS loss of $(0.05), a 106% decline compared to the prior year, primarily due to an impairment charge.

• Significant Impairment Charge

  Recorded a $794 million non-cash goodwill and intangible assets impairment charge in Q4 2025, related to the skin health business (primarily Filorga) due to underperformance.

• Full Year GAAP EPS Decline

  Full year 2025 GAAP EPS decreased 25% to $2.63, impacted by the aforementioned impairment.

• Underlying Business Growth

  Achieved Q4 net sales growth of 5.8% and organic sales growth of 2.2%, with Base Business (non-GAAP) EPS increasing 4% to $0.95.

auto_awesomeAnalysis

Colgate-Palmolive reported a substantial GAAP EPS loss for the fourth quarter and a significant decline for the full year 2025, primarily driven by a $794 million non-cash impairment charge related to its skin health business. This impairment, linked to lower-than-expected category growth and performance in China, signals challenges within that segment. Despite this, the company demonstrated underlying operational strength with positive net sales and organic sales growth, alongside an increase in non-GAAP (Base Business) EPS for both the quarter and full year. The forward-looking guidance for 2026, projecting net sales growth and double-digit GAAP EPS growth, suggests management anticipates a recovery and continued operational improvement, but the impairment remains a notable concern for the skin health portfolio.